CervoMed (NASDAQ:CRVO) Upgraded at Jones Trading

Jones Trading upgraded shares of CervoMed (NASDAQ:CRVO) from a hold rating to a buy rating in a report published on Thursday morning, Marketbeat reports. They currently have $15.00 price objective on the stock.

Other equities research analysts have also issued reports about the company. Chardan Capital upgraded CervoMed from a “neutral” rating to a “buy” rating and set a $14.00 price target on the stock in a research report on Thursday. D. Boral Capital restated a “buy” rating and issued a $10.00 price target on shares of CervoMed in a research note on Tuesday, March 11th. Morgan Stanley reiterated an “underweight” rating on shares of CervoMed in a research report on Wednesday, December 11th. Roth Capital upgraded CervoMed to a “strong-buy” rating in a research report on Thursday, December 5th. Finally, HC Wainwright lowered CervoMed from a “buy” rating to a “neutral” rating in a report on Tuesday, December 17th. One analyst has rated the stock with a sell rating, one has issued a hold rating, five have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $25.75.

CervoMed Trading Up 11.2 %

Shares of CRVO stock opened at $6.44 on Thursday. CervoMed has a fifty-two week low of $1.80 and a fifty-two week high of $26.38. The business’s 50 day moving average price is $2.45 and its 200-day moving average price is $8.04.

Hedge Funds Weigh In On CervoMed

Hedge funds have recently made changes to their positions in the business. FMR LLC bought a new position in CervoMed during the third quarter valued at approximately $56,000. Barclays PLC raised its holdings in shares of CervoMed by 323.6% in the third quarter. Barclays PLC now owns 7,748 shares of the company’s stock worth $113,000 after buying an additional 5,919 shares during the period. Virtu Financial LLC purchased a new stake in shares of CervoMed in the fourth quarter worth approximately $26,000. DRW Securities LLC purchased a new stake in shares of CervoMed in the fourth quarter worth approximately $30,000. Finally, Mariner LLC purchased a new stake in shares of CervoMed in the fourth quarter worth approximately $30,000. Institutional investors own 25.15% of the company’s stock.

CervoMed Company Profile

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery.